Inhaled amikacin adjunctive to standard-of-care intravenous antibiotic therapy was not associated with improvements in survival in mechanically ventilated patients with Gram-negative pneumonia, according to the results of a phase 3 study published in the Lancet: Infectious Diseases.

The study consisted of 2 clinical trials (INHALE 1 and INHALE 2; ClinicalTrials.gov Identifiers: NCT01799993 and NCT00805168, respectively) that were performed in 153 different hospital intensive care units across 25 countries. Researchers enrolled patients with pneumonia caused by or demonstrating 2 risk factors for a Gram-negative, multidrug-resistant pathogen. All patients were intubated and mechanically ventilated and presented with a modified Clinical Pulmonary Infection Score of ≥6.

After stratifying patients by region and disease severity, the researchers randomly assigned patients to either aerosolized 400 mg amikacin (n=255) or saline aerosolized placebo (n=253). Treatments were administered every 12 hours for 10 days alongside standard-of-care intravenous antibiotics. Survival at days 28 to 32 among patients who received ≥1 dose of the study drug was the primary end point. In addition, researchers assessed and compared safety outcomes in the 2 treatment groups.

Although the primary end point was not met, the investigators found no between-group difference between the amikacin and placebo groups in terms of survival (75% vs 77%, respectively; odds ratio [OR], 0.841; 95% CI, 0.554-1.277; P =.43). In the safety population, a prespecified supporting analysis found no difference between the groups that survived until the late follow-up visit (OR, 0.989; 95% CI, 0.694-1.408; P =.95). In addition, a similar proportion of patients in both groups experienced a treatment-emergent adverse event or serious treatment-emergent adverse event. A cumulative all-cause mortality analysis found that deaths occurred at similar rates in both groups.


Continue Reading

A limitation of the study included the variability in the standard-of-care regimens used at each center.

Related Articles

On the basis of their findings, the INHALE investigators wrote that there is no support for the use of inhaled amikacin adjunctive to standard-of-care intravenous therapy in patients receiving mechanical ventilation who have Gram-negative pneumonia.

Disclosure: This clinical trial was supported by Bayer AG. Please see the original reference for a full list of authors’ disclosures.

Reference

Niederman MS, Alder J, Bassetti M, et al. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial [published online December 19, 2019]. Lancet Infect Dis. doi:10.1016/S1473-3099(19)30574-2

This article originally appeared on Pulmonology Advisor